Streetbeat News

Analyst Ratings

C

RPAY

Citigroup analyst Andrew Schmitt maintains a Neutral rating on Repay Hldgs (NASDAQ:RPAY) and raises the price target from $7 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:50 pm

C

SOND

Citigroup analyst Ronald Josey has maintained a 'Buy' rating on Sonder Holdings (NASDAQ:SOND) but lowered the price target from $1.5 to $1.15.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:49 pm

STAG

Citigroup analyst Emmanuel Korchman has maintained a Neutral rating on Stag Industrial (NYSE:STAG) and raised the price target from $33 to $37.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:47 pm

C

VAL

Citigroup analyst Nikhil Gupta maintains a Buy rating on Valaris (NYSE:VAL) and raises the price target from $85 to $113.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:46 pm

PDD

A whale investor has taken a bullish stance on PDD Holdings (NASDAQ:PDD), with 50% of investors opening trades with bullish expectations and 50% with bearish. The whale has been targeting a price range from $60.0 to $140.0 for PDD Holdings over the last 3 months. The price of PDD is currently down -4.34% at $81.04. The next earnings are expected to be released in 17 days.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 4:45 pm

WRBY

Citigroup analyst Paul Lejuez has maintained a Neutral rating on Warby Parker (NYSE:WRBY) and raised the price target from $13 to $14.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:42 pm

C

VOYA

Citigroup analyst Michael Ward maintains a Buy rating on Voya Financial (NYSE:VOYA) and raises the price target from $85 to $86.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:37 pm

ALXO

Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on ALX Oncology Holdings (NASDAQ:ALXO) but lowered the price target from $48 to $8.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:34 pm

OPTN

Piper Sandler analyst David Amsellem has maintained an Overweight rating on OptiNose (NASDAQ:OPTN) but lowered the price target from $4 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:33 pm

RCEL

Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on AVITA Medical (NASDAQ:RCEL) and raised the price target from $18.5 to $23.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:31 pm